You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

 

Online download statistics by month:

Online download statistics by month: March 2021 to July 2025

AbstractFullPdf
Mar 2021470470170
Apr 202118418465
May 202112612650
Jun 202114414460
Jul 202112212244
Aug 202112412439
Sep 202110110139
Oct 202112712763
Nov 202111611661
Dec 202111311637
Jan 202211912488
Feb 2022909037
Mar 202210813478
Apr 202210410639
May 2022919850
Jun 2022788340
Jul 2022697226
Aug 2022969947
Sep 2022687073
Oct 2022898970
Nov 202210010263
Dec 2022777728
Jan 2023848435
Feb 202310010045
Mar 2023525432
Apr 2023717240
May 2023585838
Jun 2023595929
Jul 2023828239
Aug 2023383819
Sep 2023474815
Oct 2023484937
Nov 2023717125
Dec 2023424427
Jan 2024272814
Feb 2024434331
Mar 2024939772
Apr 2024656630
May 2024596233
Jun 2024636225
Jul 2024768535
Aug 2024545534
Sep 2024585829
Oct 202499105164
Nov 2024828445
Dec 202410610847
Jan 2025848530
Feb 2025858545
Mar 2025747537
Apr 2025949534
May 2025848547
Jun 2025525228
Jul 2025110
Total476748642428